On January 6, 2026 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), reported that the Company will participate in the American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium 2026 taking place January 8-10, 2026, in San Francisco, California. Details of the posters are included below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Poster Details:
Abstract Title: BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma.
Abstract Number: 242
Poster Board Number: K2
Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date: Saturday, January 10, 2026
Session Time: 7:00-7:55 AM
Presenter: Dr. Reema Patel

Second Poster Details:
Abstract Title: A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma.
Abstract Number: TPS273
Poster Board Number: L7
Session Title: Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date: Saturday, January 10, 2026
Session Time: 7:00-7:55 AM
Presenter: Dr. Tariq Arshad

Third Poster Details:
Abstract Title: Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
Abstract Number: 105
Poster Board Number: D17
Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date: Saturday, January 10, 2026
Session Time: 7:00-7:55 AM
Presenter: Michael Gazda, Ph.D.
The abstracts are scheduled to be posted to the ASCO (Free ASCO Whitepaper) GI Online Program at 5 PM ET on Monday, January 6.

About BXQ-350
Bexion’s lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional sphingolipid activator protein, Saposin C, and a phospholipid. Multiple Phase 1 clinical trials in adult and pediatric patients have demonstrated a robust safety profile for BXQ-350 with evidence of single agent activity across multiple solid tumor types. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in patients treated with oxaliplatin and other chemotoxic agents.

(Press release, Bexion, JAN 6, 2026, View Source [SID1234661770])